<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: To find out whether the total <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mass and post-ablation <z:mp ids='MP_0001651'>necrosis</z:mp> volume influence the disease-free survival of patients following radiofrequency ablation (RFA) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODOLOGY: Fifty nine patients with RFA of primary and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary tumors</z:e> were evaluated retrospectively in a four year period </plain></SENT>
<SENT sid="2" pm="."><plain>Total <z:e sem="disease" ids="C0240225" disease_type="Disease or Syndrome" abbrv="">liver mass</z:e>, post-ablation <z:mp ids='MP_0001651'>necrosis</z:mp> volume and their ratio were evaluated using computed tomography examination in the relationship with the risk of insufficient <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> ablation and the disease-free patients survival </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A complete ablation was performed in 51 patients, non-ablation in 8 (13.6%) patients </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e>, <z:mp ids='MP_0001651'>necrosis</z:mp> volume were 19.2±19.5, 58.7±44.7mL, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and <z:mp ids='MP_0001651'>necrosis</z:mp> mass ratio was 0.39±0.45 </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> or necroses mass volume or the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>/necroses mass ratio had no effect on the patients progression-free survival </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with a <z:mp ids='MP_0001651'>necrosis</z:mp> volume &lt;25mL had a 10-times higher risk of insufficient ablation (OR=9.9; 95% CI=1.9-51.5; p&lt;0.002) and patients with the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>/<z:mp ids='MP_0001651'>necrosis</z:mp> mass ratio &gt;0.4 had a 8-times higher risk of insufficient ablation (OR=7.9; 95% CI=1.4-44.6; p&lt;0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:mp ids='MP_0001651'>Necrosis</z:mp> volume after RFA and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>/<z:mp ids='MP_0001651'>necrosis</z:mp> mass ratio are the important factors for insufficient ablation but do not have any influence on the patients progression-free survival </plain></SENT>
</text></document>